View ValuationSOPHiA GENETICS 향후 성장Future 기준 점검 2/6SOPHiA GENETICS은 연간 수입과 매출이 각각 57.1%와 21.8% 증가할 것으로 예상되고 EPS는 연간 57.6%만큼 증가할 것으로 예상됩니다.핵심 정보57.1%이익 성장률57.58%EPS 성장률Healthcare Services 이익 성장20.4%매출 성장률21.8%향후 자기자본이익률n/a애널리스트 커버리지Low마지막 업데이트20 Jul 2026최근 향후 성장 업데이트Price Target Changed • Jul 20Price target increased by 17% to US$9.00Up from US$7.67, the current price target is an average from 4 analysts. New target price is 42% above last closing price of US$6.33. Stock is up 81% over the past year. The company is forecast to post a net loss per share of US$0.84 next year compared to a net loss per share of US$1.17 last year.공고 • May 06SOPHiA GENETICS SA Reaffirms Earnings Guidance for the Fiscal Year 2026SOPHiA GENETICS SA reaffirmed earnings guidance for the fiscal year 2026. For the year, the company expects revenue to be between $92 million and $94 million, representing approximately 20% to 22% year-over-year growth compared to the fiscal year 2025.공고 • Mar 03SOPHiA GENETICS SA Reaffirms Earnings Guidance for the Fiscal Year 2026SOPHiA GENETICS SA reaffirmed earnings guidance for the fiscal year 2026. For the year, the company expects revenue to be between $92 million and $94 million, representing approximately 20% to 22% year-over-year growth compared to the fiscal year 2025.Price Target Changed • Jan 26Price target increased by 9.5% to US$7.67Up from US$7.00, the current price target is an average from 3 analysts. New target price is 44% above last closing price of US$5.32. Stock is up 19% over the past year. The company is forecast to post a net loss per share of US$1.15 next year compared to a net loss per share of US$0.95 last year.공고 • Nov 05SOPHiA GENETICS SA Revises Earnings Guidance for the Year 2025SOPHiA GENETICS SA revised earnings guidance for the Year 2025. For the period, full year revenue is now expected to be in the range of $75 to $77 million, representing year-over-year growth of 15% to 18%. This compares to the prior range of $72 to $76 million.Major Estimate Revision • Aug 12Consensus EPS estimates fall by 12%The consensus outlook for fiscal year 2025 has been updated. 2025 expected loss increased from -US$0.96 to -US$1.08 per share. Revenue forecast unchanged at US$74.5m. Healthcare Services industry in the US expected to see average net income growth of 22% next year. Consensus price target down from US$7.25 to US$7.00. Share price fell 8.2% to US$3.14 over the past week.모든 업데이트 보기Recent updatesRecent Insider Transactions Derivative • Jul 21Co-Founder & Executive Chairman notifies of intention to sell stockJurgi Camblong intends to sell 24k shares in the next 90 days after lodging an Intent To Sell Form on the 20th of July. If the sale is conducted around the recent share price of US$5.87, it would amount to US$143k. Jurgi currently holds 3.53m shares (0.042107524875122274 of the company). Company insiders have collectively sold US$175k more than they bought, via options and on-market transactions in the last 12 months.공고 • Jul 21SOPHiA GENETICS SA to Report Q2, 2026 Results on Aug 04, 2026SOPHiA GENETICS SA announced that they will report Q2, 2026 results on Aug 04, 2026내러티브 업데이트 • Jul 21SOPH: AI Usage Model And NHS Rollout Will Drive Future UpsideAnalysts have raised their price target on SOPHiA GENETICS stock to $12, citing the company’s AI-driven, usage-based revenue model across clinical and biopharma customers, as well as its exposure to an estimated $40 billion addressable market, as key factors supporting the updated valuation and fair value assumptions. What’s in the News for SOPHiA GENETICS SOPHiA GENETICS completed a follow on equity offering of 10,526,000 common shares at US$4.75 per share, raising approximately US$49.9985 million.Price Target Changed • Jul 20Price target increased by 17% to US$9.00Up from US$7.67, the current price target is an average from 4 analysts. New target price is 42% above last closing price of US$6.33. Stock is up 81% over the past year. The company is forecast to post a net loss per share of US$0.84 next year compared to a net loss per share of US$1.17 last year.Recent Insider Transactions Derivative • Jul 01Co-Founder & Executive Chairman notifies of intention to sell stockJurgi Camblong intends to sell 70k shares in the next 90 days after lodging an Intent To Sell Form on the 30th of June. If the sale is conducted around the recent share price of US$5.98, it would amount to US$419k. Jurgi currently holds 3.62m shares (0.04316089777938126 of the company). Company insiders have collectively bought US$10k more than they sold, via options and on-market transactions, in the last 12 months.공고 • Jun 22SOPHiA GENETICS SA Approves Board ChangesSOPHiA GENETICS SA announced that at the annual general meeting held on June 18, 2026 approved that co-founder Dr. Jurgi Camblong elected as Executive Chairman of the Board, Ross Muken elected as new member of the Board ahead of his appointment as CEO effective July 1, 2026.New Risk • Jun 21New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 23% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$27m net loss in 3 years). Shareholders have been diluted in the past year (23% increase in shares outstanding).Seeking Alpha • Jun 18SOPHiA Genetics: Strong Growth Meets A Critical Execution PhaseSummary SOPHiA GENETICS is approaching an inflection point in precision medicine, leveraging AI-driven genomic analysis as sequencing costs decline and data complexity rises. SOPH's platform benefits from a self-reinforcing data flywheel, with 2.5 million genomic profiles and 537 institutions using SOPHiA DDM across 75 countries. Revenue grew 22% year-over-year to $21.7M in 1Q26, with 117% net dollar retention and adjusted gross margin of 75.4%, but profitability remains a key watchpoint. Management targets adjusted EBITDA breakeven by end-2026 and profitability in 2027, supported by cost discipline, new high-value applications, and expanding customer adoption. Read the full article on Seeking Alpha공고 • Jun 17+ 1 more updateSOPHiA GENETICS SA has completed a Follow-on Equity Offering in the amount of $49.9985 million.SOPHiA GENETICS SA has completed a Follow-on Equity Offering in the amount of $49.9985 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 10,526,000 Price\Range: $4.75내러티브 업데이트 • Jun 15SOPH: New Partnerships And Ai Collaboration Will Support Future Precision OncologyAnalysts have increased their price target on SOPHiA GENETICS by $1, reflecting updated views on fair value, discount rate, revenue growth, profit margin and future P/E assumptions. What's in the News SOPHiA GENETICS signed a Memorandum of Understanding with Memorial Sloan Kettering Cancer Center to form a joint venture that aims to combine Memorial Sloan Kettering Cancer Center clinical data with the SOPHiA DDM Ai platform for multimodal precision oncology research and deployment.Recent Insider Transactions • Jun 07Executive VP & CFO recently bought US$99k worth of stockOn the 5th of June, George Cardoza bought around 20k shares on-market at roughly US$4.95 per share. This transaction amounted to 6.9% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was George's only on-market trade for the last 12 months.내러티브 업데이트 • Jun 01SOPH: NHS Liquid Biopsy Rollout Will Support Future Upside PotentialAnalysts have lifted their price target on SOPHiA GENETICS by $1, citing updated models that reflect a lower discount rate, adjusted revenue growth and profit margin assumptions, and a revised future P/E estimate. What's in the News SOPHiA GENETICS partnered with Synnovis, a leading pathology provider in England, to roll out liquid biopsy testing for lung and breast cancer patients across the U.K. under NHS England's blood test first program, using the MSK-ACCESS® test powered by SOPHiA DDM™.Recent Insider Transactions Derivative • May 20Executive VP notifies of intention to sell stockPhilippe Menu intends to sell 16k shares in the next 90 days after lodging an Intent To Sell Form on the 19th of May. If the sale is conducted around the recent share price of US$4.69, it would amount to US$73k. Since March 2026, Philippe's direct individual holding has increased from 173.62k shares to 256.39k. Company insiders have collectively sold US$3.4k more than they bought, via options and on-market transactions in the last 12 months.내러티브 업데이트 • May 15SOPH: New NHS Partnerships Will Support Future Precision Oncology AdoptionAnalysts recently lifted their price target on SOPHiA GENETICS by $1, citing updated assumptions around fair value, discount rate, revenue growth, profit margin and future P/E that together support a slightly higher valuation framework for the stock. Analyst Commentary Recent research has framed the updated price target as a fine tuning of prior assumptions rather than a major shift in conviction.Reported Earnings • May 06First quarter 2026 earnings: Revenues exceed analysts expectations while EPS lags behindFirst quarter 2026 results: US$0.27 loss per share (further deteriorated from US$0.26 loss in 1Q 2025). Revenue: US$21.7m (up 22% from 1Q 2025). Net loss: US$19.3m (loss widened 11% from 1Q 2025). Revenue exceeded analyst estimates by 6.3%. Earnings per share (EPS) missed analyst estimates by 11%. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Healthcare Services industry in the US. Over the last 3 years on average, earnings per share has increased by 3% per year and the company’s share price has also increased by 3% per year.공고 • May 06SOPHiA GENETICS SA Reaffirms Earnings Guidance for the Fiscal Year 2026SOPHiA GENETICS SA reaffirmed earnings guidance for the fiscal year 2026. For the year, the company expects revenue to be between $92 million and $94 million, representing approximately 20% to 22% year-over-year growth compared to the fiscal year 2025.내러티브 업데이트 • Apr 24SOPH: Higher Future P/E Assumptions Will Support Upside PotentialAnalysts lifted their price target on SOPHiA GENETICS by about $0.33 to $8.00, citing updated assumptions around fair value, discount rate, and future P/E that reflect recent research from multiple firms. Analyst Commentary Recent Street research has pointed to updated assumptions around fair value, the discount rate, and forward P/E as the main drivers behind the refreshed $8.00 price target on SOPHiA GENETICS.공고 • Apr 21SOPHiA GENETICS SA to Report Q1, 2026 Results on May 05, 2026SOPHiA GENETICS SA announced that they will report Q1, 2026 results Pre-Market on May 05, 2026내러티브 업데이트 • Apr 09SOPH: New U.S. Health System Partnerships Will Drive Future UpsideAnalysts have raised their price target on SOPHiA GENETICS by $1, reflecting updated views on the company’s discount rate, revenue growth outlook, profit margin assumptions, and future P/E as highlighted in recent Street research. Analyst Commentary Recent Street research around SOPHiA GENETICS points to a more cautious tone, even as price targets are adjusted to reflect updated assumptions around discount rates, revenue growth, profit margins, and future P/E multiples.내러티브 업데이트 • Mar 26SOPH: Higher Future P/E And New U.S. Partnerships Will Support UpsideAnalysts raised their price target on SOPHiA GENETICS by $1, reflecting updated views on factors such as revenue growth expectations, discount rate assumptions, profit margin outlook, and a recalibrated future P/E multiple. Analyst Commentary Bullish Takeaways Bullish analysts see the higher price target as better aligning the stock with updated expectations for revenue growth, which they view as supportive of a richer valuation multiple.내러티브 업데이트 • Mar 11SOPH: New US Health System Deals Will Support Future UpsideAnalysts lifted their fair value estimate for SOPHiA GENETICS by $1.00 to $7.00, citing updated assumptions for growth, profitability, and future P/E that align with the recent $1 upward move in the Street price target. Analyst Commentary While the latest fair value move to $7.00 lines up with the recent Street price target adjustment, not everyone is leaning positive.Reported Earnings • Mar 04Full year 2025 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2025 results: US$1.17 loss per share (further deteriorated from US$0.95 loss in FY 2024). Revenue: US$77.3m (up 19% from FY 2024). Net loss: US$79.0m (loss widened 26% from FY 2024). Revenue exceeded analyst estimates by 1.0%. Earnings per share (EPS) missed analyst estimates by 2.0%. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare Services industry in the US. Over the last 3 years on average, earnings per share has increased by 6% per year whereas the company’s share price has increased by 11% per year.공고 • Mar 03SOPHiA GENETICS SA Reaffirms Earnings Guidance for the Fiscal Year 2026SOPHiA GENETICS SA reaffirmed earnings guidance for the fiscal year 2026. For the year, the company expects revenue to be between $92 million and $94 million, representing approximately 20% to 22% year-over-year growth compared to the fiscal year 2025.내러티브 업데이트 • Feb 25SOPH: Higher Implied P/E And New Partnerships Will Support Future Platform AdoptionAnalysts have raised their price target on SOPHiA GENETICS by $1, citing updated assumptions on discount rate and long term profitability that result in a slightly higher implied future P/E of 79.26x. Analyst Commentary Analysts raising the price target by $1 are essentially saying that, based on their updated models, the shares now justify a slightly richer valuation, reflected in the implied future P/E of 79.26x.내러티브 업데이트 • Feb 10SOPH: Oncology Collaboration And New Leadership Will Support Future Platform AdoptionAnalysts have nudged their price target on SOPHiA GENETICS higher by about US$1, reflecting updated views on the company that are consistent with recent Street research commentary. Analyst Commentary Bullish Takeaways Bullish analysts connect the roughly US$1 price target adjustment to refreshed expectations on how SOPHiA GENETICS can execute on its roadmap.내러티브 업데이트 • Jan 27SOPH: Higher Price Work Will Highlight Expanding Oncology CollaborationsAnalysts have increased their price target on SOPHiA GENETICS by US$1, citing updated assumptions around fair value, discount rates, revenue growth, profit margins, and future P/E expectations. Analyst Commentary Analysts lifting their fair value assumptions by US$1 are essentially fine tuning how they see SOPHiA GENETICS balancing growth potential, execution risk, and valuation multiples such as P/E over time.Price Target Changed • Jan 26Price target increased by 9.5% to US$7.67Up from US$7.00, the current price target is an average from 3 analysts. New target price is 44% above last closing price of US$5.32. Stock is up 19% over the past year. The company is forecast to post a net loss per share of US$1.15 next year compared to a net loss per share of US$0.95 last year.공고 • Jan 13+ 2 more updatesSophia Genetics Sa Appoints Kevin Puylaert as Chief Sales Officer, Effective January 2026SOPHiA GENETICS SA announced that Kevin Puylaert, the company's current Managing Director of EMEA, is appointed Chief Sales Officer effective January 2026. Kevin has been with SOPHiA GENETICS for more than 10 years, during which he has held multiple senior leadership roles, and his contributions have been instrumental to the company's growth.공고 • Jan 12SOPHiA GENETICS SA to Report Q4, 2025 Results on Mar 03, 2026SOPHiA GENETICS SA announced that they will report Q4, 2025 results on Mar 03, 2026Recent Insider Transactions Derivative • Dec 31Co-Founder notifies of intention to sell stockJurgi Camblong intends to sell 30k shares in the next 90 days after lodging an Intent To Sell Form on the 29th of December. If the sale is conducted around the recent share price of US$4.73, it would amount to US$142k. Since March 2025, Jurgi has owned 2.65m shares directly. There have been no trades via on-market transactions or options from company insiders in the last 12 months.Recent Insider Transactions Derivative • Nov 12Co-Founder notifies of intention to sell stockJurgi Camblong intends to sell 25k shares in the next 90 days after lodging an Intent To Sell Form on the 10th of November. If the sale is conducted around the recent share price of US$4.37, it would amount to US$108k. Since March 2025, Jurgi has owned 2.65m shares directly. There have been no trades via on-market transactions or options from company insiders in the last 12 months.공고 • Nov 05SOPHiA GENETICS SA Revises Earnings Guidance for the Year 2025SOPHiA GENETICS SA revised earnings guidance for the Year 2025. For the period, full year revenue is now expected to be in the range of $75 to $77 million, representing year-over-year growth of 15% to 18%. This compares to the prior range of $72 to $76 million.Reported Earnings • Nov 05Third quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behindThird quarter 2025 results: US$0.30 loss per share (further deteriorated from US$0.28 loss in 3Q 2024). Revenue: US$19.5m (up 23% from 3Q 2024). Net loss: US$20.0m (loss widened 8.6% from 3Q 2024). Revenue exceeded analyst estimates by 7.4%. Earnings per share (EPS) missed analyst estimates by 24%. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare Services industry in the US. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has increased by 37% per year, which means it is tracking significantly ahead of earnings growth.공고 • Oct 21SOPHiA GENETICS SA to Report Q3, 2025 Results on Nov 04, 2025SOPHiA GENETICS SA announced that they will report Q3, 2025 results Pre-Market on Nov 04, 2025분석 기사 • Sep 30Market Participants Recognise SOPHiA GENETICS SA's (NASDAQ:SOPH) Revenues Pushing Shares 28% HigherSOPHiA GENETICS SA ( NASDAQ:SOPH ) shares have continued their recent momentum with a 28% gain in the last month alone...New Risk • Sep 26New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$31m net loss in 3 years). Share price has been volatile over the past 3 months (12% average weekly change).Recent Insider Transactions Derivative • Sep 24Independent Non-Executive Director notifies of intention to sell stockVincent Ossipow intends to sell 21k shares in the next 90 days after lodging an Intent To Sell Form on the 23rd of September. If the sale is conducted around the recent share price of US$3.93, it would amount to US$83k. Since March 2025, Vincent has owned 443.81k shares directly. There have been no trades via on-market transactions or options from company insiders in the last 12 months.Recent Insider Transactions Derivative • Aug 20Co-Founder notifies of intention to sell stockJurgi Camblong intends to sell 41k shares in the next 90 days after lodging an Intent To Sell Form on the 19th of August. If the sale is conducted around the recent share price of US$3.49, it would amount to US$142k. Since March 2025, Jurgi has owned 2.65m shares directly. There have been no trades via on-market transactions or options from company insiders in the last 12 months.Major Estimate Revision • Aug 12Consensus EPS estimates fall by 12%The consensus outlook for fiscal year 2025 has been updated. 2025 expected loss increased from -US$0.96 to -US$1.08 per share. Revenue forecast unchanged at US$74.5m. Healthcare Services industry in the US expected to see average net income growth of 22% next year. Consensus price target down from US$7.25 to US$7.00. Share price fell 8.2% to US$3.14 over the past week.분석 기사 • Aug 08Analysts Are Updating Their SOPHiA GENETICS SA (NASDAQ:SOPH) Estimates After Its Second-Quarter ResultsNasdaqGS:SOPH 1 Year Share Price vs Fair Value Explore SOPHiA GENETICS's Fair Values from the Community and select...공고 • Aug 06SOPHiA GENETICS SA has filed a Follow-on Equity Offering in the amount of $50 million.SOPHiA GENETICS SA has filed a Follow-on Equity Offering in the amount of $50 million. Security Name: Ordinary Shares Security Type: Common Stock Transaction Features: At the Market Offering내러티브 업데이트 • Aug 06Precision Medicine Advances Will Transform Global Healthcare AnalyticsSOPHiA GENETICS' consensus price target has been reduced to $6.75, primarily reflecting lowered revenue growth expectations despite a modest improvement in net profit margin. What's in the News SOPHiA GENETICS reiterated its full-year 2025 revenue guidance of $72 million to $76 million.Reported Earnings • Aug 05Second quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behindSecond quarter 2025 results: US$0.33 loss per share (further deteriorated from US$0.23 loss in 2Q 2024). Revenue: US$18.3m (up 16% from 2Q 2024). Net loss: US$22.4m (loss widened 48% from 2Q 2024). Revenue exceeded analyst estimates by 4.8%. Earnings per share (EPS) missed analyst estimates by 38%. Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 10.0% growth forecast for the Healthcare Services industry in the US. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.공고 • Aug 05SOPHiA GENETICS SA Reiterates Earnings Guidance for the Year 2025SOPHiA GENETICS SA reiterated earnings guidance for the year 2025. The company reiterated full-year guidance of revenue between $72 million and $76 million.공고 • Jul 22SOPHiA GENETICS SA to Report Q2, 2025 Results on Aug 05, 2025SOPHiA GENETICS SA announced that they will report Q2, 2025 results Pre-Market on Aug 05, 2025분석 기사 • Jul 10Revenues Tell The Story For SOPHiA GENETICS SA (NASDAQ:SOPH) As Its Stock Soars 29%SOPHiA GENETICS SA ( NASDAQ:SOPH ) shareholders have had their patience rewarded with a 29% share price jump in the...Recent Insider Transactions Derivative • Jun 22Independent Non-Executive Director notifies of intention to sell stockVincent Ossipow intends to sell 18k shares in the next 90 days after lodging an Intent To Sell Form on the 20th of June. If the sale is conducted around the recent share price of US$3.04, it would amount to US$56k. Since March 2025, Vincent has owned 443.81k shares directly. There have been no trades via on-market transactions or options from company insiders in the last 12 months.Recent Insider Transactions Derivative • May 20Co-Founder notifies of intention to sell stockJurgi Camblong intends to sell 43k shares in the next 90 days after lodging an Intent To Sell Form on the 19th of May. If the sale is conducted around the recent share price of US$2.96, it would amount to US$128k. Since March 2025, Jurgi has owned 2.65m shares directly. There have been no trades via on-market transactions or options from company insiders in the last 12 months.공고 • May 10SOPHiA GENETICS SA, Annual General Meeting, Jun 18, 2025SOPHiA GENETICS SA, Annual General Meeting, Jun 18, 2025, at 14:00 W. Europe Standard Time. Location: la piece 12, 1180 rolle/vd, SwitzerlandReported Earnings • May 08First quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behindFirst quarter 2025 results: US$0.26 loss per share (further deteriorated from US$0.21 loss in 1Q 2024). Revenue: US$17.8m (up 13% from 1Q 2024). Net loss: US$17.4m (loss widened 27% from 1Q 2024). Revenue exceeded analyst estimates by 6.1%. Earnings per share (EPS) missed analyst estimates by 5.7%. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 10.0% growth forecast for the Healthcare Services industry in the US. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.공고 • May 06SOPHiA GENETICS SA Provides Reiterates Guidance for the Year 2025SOPHiA GENETICS SA provided reiterated guidance for the year 2025. Full-year revenue between $72 million and $76 million, representing growth of approximately 10% to 17% compared to full year of 2024.공고 • Apr 22SOPHiA GENETICS SA to Report Q1, 2025 Results on May 06, 2025SOPHiA GENETICS SA announced that they will report Q1, 2025 results Pre-Market on May 06, 2025새로운 내러티브 • Apr 02Expedited Implementation And New US Signings Will Boost Future Impact Expansion in the U.S. market and major new customer acquisitions like Mount Sinai are poised to significantly boost revenue and market share.분석 기사 • Mar 20With A 25% Price Drop For SOPHiA GENETICS SA (NASDAQ:SOPH) You'll Still Get What You Pay ForSOPHiA GENETICS SA ( NASDAQ:SOPH ) shareholders won't be pleased to see that the share price has had a very rough...Reported Earnings • Mar 04Full year 2024 earnings: Revenues and EPS in line with analyst expectationsFull year 2024 results: US$0.95 loss per share (improved from US$1.22 loss in FY 2023). Revenue: US$65.2m (up 4.5% from FY 2023). Net loss: US$62.5m (loss narrowed 21% from FY 2023). Revenue was in line with analyst estimates. Earnings per share (EPS) were also in line with analyst expectations. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 9.7% growth forecast for the Healthcare Services industry in the US. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 34% per year, which means it is significantly lagging earnings.공고 • Mar 04SOPHiA GENETICS SA Provides Earnings Guidance for the Year 2025SOPHiA GENETICS SA provided earnings guidance for the year 2025. Full-year revenue between $72 million and $76 million, representing growth of approximately 10% to 17% compared to full year of 2024.Recent Insider Transactions Derivative • Feb 20Co-Founder notifies of intention to sell stockJurgi Camblong intends to sell 90k shares in the next 90 days after lodging an Intent To Sell Form on the 19th of February. If the sale is conducted around the recent share price of US$4.46, it would amount to US$404k. Jurgi currently holds 2.46m shares (0.037027890189429806 of the company). There have been no trades via on-market transactions or options from company insiders in the last 12 months.공고 • Feb 18SOPHiA GENETICS SA to Report Q4, 2024 Results on Mar 04, 2025SOPHiA GENETICS SA announced that they will report Q4, 2024 results Pre-Market on Mar 04, 2025공고 • Jan 29SOPHiA GENETICS Launches Comprehensive MRD Tracking CapabilitiesSOPHiA GENETICS has unveiled the OncoPortal™ Mutation Tracker — a longitudinal MRD tracking tool designed for disease monitoring in the context of oncology. This innovation underscores SOPHiA GENETICS' commitment to advancing data-driven approaches for improved oncology insights. Tracking genomic variants across multiple time points in the same patient is becoming increasingly critical in cancer care, particularly for identifying treatment resistance or detecting residual cancer cells, such as in Measurable Residual Disease (MRD) management. The integration of longitudinal tracking capabilities with next-generation sequencing (NGS) allow the parallel detection of cancer-specific genetic mutations at very low frequencies. This combined approach enables early identification of residual disease or emerging variants, providing a more precise assessment of disease burden, better stratification of high-risk patients, and the ability to tailor treatments to the cancer's unique genomic profile. The OncoPortal™ Mutation Tracker augments the SOPHiA DDM™ Platform's core analytical capabilities to allow clinical researchers to longitudinally monitor evolving genomic variants across multiple time points, providing a comprehensive view of disease evolution. The OncoPortal™ Mutation Tracker enhances workflow efficiency for longitudinal variant tracking by offering flexible low frequency variant selection, customizable threshold settings, and reporting features to generate longitudinal graphical representations, simplifying the process of tracking and analyzing genetic changes over time.Recent Insider Transactions Derivative • Jan 26Co-Founder notifies of intention to sell stockJurgi Camblong intends to sell 19k shares in the next 90 days after lodging an Intent To Sell Form on the 24th of January. If the sale is conducted around the recent share price of US$4.33, it would amount to US$81k. Since March 2024, Jurgi has owned 2.46m shares directly. There have been no trades via on-market transactions or options from company insiders in the last 12 months.New Risk • Jan 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$43m net loss in 3 years). Share price has been volatile over the past 3 months (11% average weekly change).분석 기사 • Jan 10Shareholders Should Be Pleased With SOPHiA GENETICS SA's (NASDAQ:SOPH) PriceWhen close to half the companies in the Healthcare Services industry in the United States have price-to-sales ratios...Recent Insider Transactions Derivative • Dec 27Co-Founder notifies of intention to sell stockJurgi Camblong intends to sell 40k shares in the next 90 days after lodging an Intent To Sell Form on the 24th of December. If the sale is conducted around the recent share price of US$3.31, it would amount to US$134k. Since March 2024, Jurgi has owned 2.46m shares directly. There have been no trades via on-market transactions or options from company insiders in the last 12 months.New Risk • Nov 11New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.0% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$39m net loss in 3 years). Share price has been volatile over the past 3 months (9.9% average weekly change). Shareholders have been diluted in the past year (2.0% increase in shares outstanding).공고 • Nov 06SOPHiA GENETICS SA Announces Chief Financial Officer ChangesSOPHiA GENETICS SA announced that Ross Muken, previously Chief Financial Officer ("CFO") and Chief Operating Officer ("COO"), has been promoted to company President, effective November 5, 2024. George Cardoza has been appointed as the company's new CFO. In the newly created role of company President, Ross Muken will oversee SOPHiA GENETICS's global business operations and work even more closely on strategic planning with CEO, Jurgi Camblong. He will continue to lead the company's go-to-market function, including Clinical sales, BioPharma Dx sales, sales support, marketing, customer experience, and operations. Ross joined SOPHiA GENETICS in February 2021 as CFO and was appointed as CFO and COO in March 2023. As CFO, Cardoza will oversee all corporate finance functions, including accounting, financial planning and analysis ("FP&A"), investor relations, internal audit, tax, and treasury. Mr. Cardoza brings more than 30 years of experience in the precision medicine and clinical diagnostics industry, with extensive experience in both financial and operational leadership. Before joining SOPHiA GENETICS, he was the CFO and Head of Service Delivery at Biocartis. Prior, he spent over twelve years with NeoGenomics Laboratories in several executive roles (CFO, President Pharma Services Division, and President and Chief Operating Officer Laboratory Operations), and previously spent more than fourteen years with Quest Diagnostics in various roles including Controller of the Central Region. Throughout his career, Cardoza has shown a strong talent for financial management, strategic planning, and driving businesses towards increasing levels of performance. He has a deep understanding of the industry landscape and a proven track record of success in executing and influencing growth-oriented business strategies. Mr. Cardoza holds a B.S. in Finance and Accounting from Syracuse University and an MBA from Michigan State University.Reported Earnings • Nov 05Third quarter 2024 earnings: EPS and revenues miss analyst expectationsThird quarter 2024 results: US$0.28 loss per share (further deteriorated from US$0.21 loss in 3Q 2023). Revenue: US$15.9m (down 2.8% from 3Q 2023). Net loss: US$18.4m (loss widened 33% from 3Q 2023). Revenue missed analyst estimates by 1.3%. Earnings per share (EPS) also missed analyst estimates by 19%. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 9.6% growth forecast for the Healthcare Services industry in the US. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 37% per year, which means it is significantly lagging earnings.공고 • Nov 05SOPHiA GENETICS Re-Affirms Earnings Guidance for the Year 2024SOPHiA GENETICS re-affirmed earnings guidance for the year 2024. For the year, the company expects revenue to be between $65 million and $67 million, representing growth of 4% to 7% compared to Fiscal Year 2023.공고 • Oct 23SOPHiA GENETICS SA to Report Q3, 2024 Results on Nov 05, 2024SOPHiA GENETICS SA announced that they will report Q3, 2024 results Pre-Market on Nov 05, 2024Recent Insider Transactions Derivative • Oct 06Co-Founder notifies of intention to sell stockJurgi Camblong intends to sell 21k shares in the next 90 days after lodging an Intent To Sell Form on the 4th of October. If the sale is conducted around the recent share price of US$3.24, it would amount to US$70k. Since March 2024, Jurgi has owned 2.46m shares directly. There have been no trades via on-market transactions or options from company insiders in the last 12 months.분석 기사 • Oct 03Is SOPHiA GENETICS (NASDAQ:SOPH) A Risky Investment?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...공고 • Sep 16SOPHiA GENETICS Presents Multimodal Research on AI-Driven Patient Stratification at ESMO 2024SOPHiA GENETICS will unveil new research at the European Society for Medical Oncology (ESMO) 2024. The study, conducted in collaboration with AstraZeneca, leverages advanced AI-driven techniques to identify subgroups of stage IV non-small cell lung cancer (NSCLC) patients who could most benefit from the addition of tremelimumab to durvalumab and chemotherapy. The research is a retrospective, multimodal analysis of the POSEIDON Phase 3 clinical trial (NCT03164616). This trial originally demonstrated that the combination of tremelimumab, durvalumab, and chemotherapy significantly increases progression-free survival (PFS) and overall survival (OS) versus chemotherapy in patients with metastatic NSCLC, which lead to approval of this regiment globally in 1L mNSCLC. The SOPHiA GENETICS study used cutting-edge multimodal machine learning models to analyze clinical, biological, genomic, and imaging data, pinpointing patient subgroups who are most likely to benefit from the combination treatment. The research highlighted signatures identifying patients with non-squamous metastatic NSCLC who may derive higher OS benefit from the addition of tremelimumab to durvalumab plus chemotherapy in the first-line treatment setting. In particular, EGFR wild-type, FGFR3 wild-type, CDKN2A wild-type, KRAS mutation, and STK11 mutation comprised elements of a signature was identified as being associated with a higher OS benefit. These findings could have significant implications for the treatment of NSCLC, as it provides an exploration avenue towards a more tailored approach to patient care. The study will be presented as a poster by Ferdinandos Skoulidis, Department of Thoracic Medical Oncology, University of Texas MD Anderson Cancer Center at ESMO 2024 hosted in Barcelona, Spain from September 13-17, 2024. His presentation showcases the operational feasibility and clinical impact of large-scale multimodal analyses in identifying heterogeneous treatment effects in oncology.Recent Insider Transactions Derivative • Sep 11Independent Non-Executive Director notifies of intention to sell stockKathy Hibbs intends to sell 16k shares in the next 90 days after lodging an Intent To Sell Form on the 9th of September. If the sale is conducted around the recent share price of US$3.75, it would amount to US$60k. Since March 2024, Kathy has owned 37.41k shares directly. There have been no trades via on-market transactions or options from company insiders in the last 12 months.공고 • Sep 04SOPHiA GENETICS SA Unveils New Generation of the Sophia Ddmtm Platform At Morgan Stanley Healthcare Conference 2024SOPHiA GENETICS launched the new generation of the SOPHiA DDMTM Platform. The new-gen SOPHiA DDMTM Platform offers a new architecture designed to more efficiently compute large amounts of data at-scale, while elevating customer experience with integrated access to multimodal analytics modules. As cancer cases continue to rise across the globe, understanding of the disease becomes more nuanced. Newer, more effective therapies are being developed each day, and data is becoming increasingly critical in diagnosis, therapy selection, and drug development. Since launching the first generation of SOPHiA DDM TM in 2015, the Platform has been at the forefront of these innovations, accelerating the practice of data driven medicine globally as a leading platform in healthcare for using data to improve patient care. Data computed daily by the Platform has surged over the years with over 1.8 million genomic profiles being analyzed on the platform, at a rate of almost 30,000 analyses per month. As the volume and utility of data grows, SOPHiA GENETICS continues to accelerate innovation in the field of data-driven medicine by unveiling best-in-class technology and data science capabilities. The new generation SOPHiA DDM TM Platform offers a new, web-based architecture, which allows the Platform to compute and process data more efficiently by leveraging microservices as well as the newest technologies in cloud computing and GPUs from partners such as NVIDIA and Microsoft. Faster data processing not only optimizes computing, but it also provides answers more rapidly. Customers will experience faster turnaround time from data upload to insights. In addition, more efficient data processing capabilities enable the launch of new capabilities, such as the new whole genome sequencing (WGS) application being released later this year. It also enables new capabilities in multimodal analytics, which require processing of more complex and sizeable data sets across data modalities. Under the new generation of SOPHiA DDMTM, genomic, radiomic, and multimodal analytics capabilities will be offered in a single, integrated workspace. Customers benefit from the three analytics modules by selecting applications that best suit their needs: Genomics: Ingests genomics FASTQ and VCF data to efficiently call, annotate, and pre-classify oncogenic or pathogenic variants. Radiomics: Processes data from various imaging modalities (e.g., CT scans, PET-CT, MRI), segments anatomical areas of interest, and extracts radiomic features for further analysis. Multimodal: Aggregates data from the radiomics and genomics modules, along with processed clinical, biological, and histological data, to train and verify predictive models at the individual patient level.Major Estimate Revision • Aug 13Consensus revenue estimates decrease by 13%, EPS upgradedThe consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from US$76.0m to US$65.9m. EPS estimate increased from -US$0.995 to -US$0.917 per share. Healthcare Services industry in the US expected to see average net income growth of 26% next year. Consensus price target down from US$8.00 to US$6.00. Share price fell 23% to US$3.19 over the past week.Recent Insider Transactions Derivative • Aug 11Independent Non-Executive Director notifies of intention to sell stockKathy Hibbs intends to sell 16k shares in the next 90 days after lodging an Intent To Sell Form on the 9th of August. If the sale is conducted around the recent share price of US$3.36, it would amount to US$53k. Since March 2024, Kathy has owned 37.41k shares directly. There have been no trades via on-market transactions or options from company insiders in the last 12 months.분석 기사 • Aug 09SOPHiA GENETICS SA (NASDAQ:SOPH) Just Reported, And Analysts Assigned A US$6.00 Price TargetShareholders in SOPHiA GENETICS SA ( NASDAQ:SOPH ) had a terrible week, as shares crashed 25% to US$3.36 in the week...분석 기사 • Aug 08Investors Still Waiting For A Pull Back In SOPHiA GENETICS SA (NASDAQ:SOPH)When you see that almost half of the companies in the Healthcare Services industry in the United States have...Price Target Changed • Aug 07Price target decreased by 25% to US$6.00Down from US$8.00, the current price target is an average from 4 analysts. New target price is 64% above last closing price of US$3.65. Stock is up 1.1% over the past year. The company is forecast to post a net loss per share of US$0.92 next year compared to a net loss per share of US$1.22 last year.공고 • Aug 06SOPHiA GENETICS SA Provides Earnings Guidance for the Year 2024SOPHiA GENETICS SA provided earnings guidance for the year 2024. For the period, the company Full-year revenue is now expected to be between $65 million and $67 million, representing growth of 4% to 7% compared to Fiscal Year 2023.공고 • Jul 23SOPHiA GENETICS SA to Report Q2, 2024 Results on Aug 06, 2024SOPHiA GENETICS SA announced that they will report Q2, 2024 results Pre-Market on Aug 06, 2024Recent Insider Transactions Derivative • Jul 08Co-Founder notifies of intention to sell stockJurgi Camblong intends to sell 22k shares in the next 90 days after lodging an Intent To Sell Form on the 5th of July. If the sale is conducted around the recent share price of US$4.66, it would amount to US$103k. Since March 2024, Jurgi has owned 2.46m shares directly. There have been no trades via on-market transactions or options from company insiders in the last 12 months.Board Change • Jul 05Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 2 highly experienced directors. Independent Director Jean-Michel Yves Cossery was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.공고 • Jun 24Sophia Genetics S. A. Launches New Residual Acute Myeloid ApplicationSophia Genetics S.A. announced its new Residual Acute Myeloid (RAM) Application. The new offering expands the company's comprehensive oncology portfolio to support measurable residual disease (MRD) capabilities and will be available to customers worldwide this summer. Acute Myeloid Leukemia (AML) represents about one percent of all cancers worldwide, yet is one of the most common forms of leukemia in adults1. Over 50 percent of AML patients relapse within 3 years after achieving complete remission2, therefore post-treatment monitoring is imperative for AML patients, particularly within the first two years, to help quickly detect any signs of relapse3. MRD solutions can help inform post-remission therapy and identify early relapse, and serve as a primary endpoint in clinical trials, helping researchers detect even the smallest trace of cancer and support better patient outcomes. Next-generation sequencing (NGS)-based MRD testing is among the most advanced in cancer screening and monitoring, and can be found only with highly sensitive methods. The SOPHiA DDM™ RAM Solution provides users with the confidence that MRD will detect even one cancer cell among 10,000 cells. This application will allow users to stay ahead of disease response with the analytical capabilities of the SOPHiA DDM™ Platform, enabling sensitive variant detection down to 0.01% VAF and covering guideline-recommended genes to deliver robust insights for residual acute myeloid. Customers using the SOPHiA DDM™ RAM Solution will have access to longitudinal variant monitoring, allowing them to visualize the mutational landscape for each patient and its evolution over time. The solution also provides users with the most up-to-date databases and customizable reporting features to generate graphical representations and comprehensive MRD reports. Additionally, the SOPHiA DDM™ RAM Solution will continually hone its machine learning algorithms to provide the most accurate MRD results in just four days.Recent Insider Transactions Derivative • Jun 16Executive VP notifies of intention to sell stockPhilippe Menu intends to sell 33k shares in the next 90 days after lodging an Intent To Sell Form on the 13th of June. If the sale is conducted around the recent share price of US$4.80, it would amount to US$158k. Since March 2024, Philippe has owned 41.75k shares directly. There have been no trades via on-market transactions or options from company insiders in the last 12 months.Recent Insider Transactions Derivative • May 31Executive VP & Chief Scientific Officer notifies of intention to sell stockZhenyu Xu intends to sell 12k shares in the next 90 days after lodging an Intent To Sell Form on the 29th of May. If the sale is conducted around the recent share price of US$4.92, it would amount to US$59k. Since March 2024, Zhenyu has owned 414.25k shares directly. There have been no trades via on-market transactions or options from company insiders in the last 12 months.공고 • May 19SOPHiA GENETICS SA, Annual General Meeting, Jun 24, 2024SOPHiA GENETICS SA, Annual General Meeting, Jun 24, 2024, at 14:00 W. Europe Standard Time. Location: offices of sophia genetics sa, la piece 12, 1180 rolle vd, SwitzerlandReported Earnings • May 08First quarter 2024 earnings released: US$0.21 loss per share (vs US$0.31 loss in 1Q 2023)First quarter 2024 results: US$0.21 loss per share (improved from US$0.31 loss in 1Q 2023). Revenue: US$15.8m (up 13% from 1Q 2023). Net loss: US$13.7m (loss narrowed 30% from 1Q 2023). Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare Services industry in the US.공고 • May 08SOPHiA GENETICS Reiterates Earnings Guidance for the Full Year 2024SOPHiA GENETICS reiterated earnings guidance for the full year 2024. Based on information as of May 7, 2024, SOPHiA GENETICS is reaffirming previously provided guidance of: revenue between $78 million and $81 million, representing growth of 25% to 30% compared to full year 2023 revenue.공고 • Apr 24SOPHiA GENETICS SA to Report Q1, 2024 Results on May 07, 2024SOPHiA GENETICS SA announced that they will report Q1, 2024 results Pre-Market on May 07, 2024Major Estimate Revision • Mar 12Consensus EPS estimates fall by 11%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from US$82.1m to US$79.8m. Losses expected to increase from US$0.91 per share to US$1.01. Healthcare Services industry in the US expected to see average net income growth of 32% next year. Consensus price target up from US$8.33 to US$8.67. Share price fell 14% to US$4.85 over the past week.분석 기사 • Mar 09SOPHiA GENETICS SA (NASDAQ:SOPH) Full-Year Results Just Came Out: Here's What Analysts Are Forecasting For This YearSOPHiA GENETICS SA ( NASDAQ:SOPH ) shareholders are probably feeling a little disappointed, since its shares fell 2.3...Price Target Changed • Mar 06Price target increased by 8.3% to US$8.67Up from US$8.00, the current price target is an average from 3 analysts. New target price is 73% above last closing price of US$5.01. Stock is up 63% over the past year. The company is forecast to post a net loss per share of US$0.94 next year compared to a net loss per share of US$1.22 last year.공고 • Mar 06SOPHiA GENETICS SA Provides Earnings Guidance for 2024SOPHiA GENETICS is provided earnings guidance for 2024. For the period, company expects Revenue between $78 million and $81 million, representing growth of 25% to 30% compared to full year 2023.Reported Earnings • Mar 06Full year 2023 earnings: EPS misses analyst expectationsFull year 2023 results: US$1.22 loss per share (improved from US$1.36 loss in FY 2022). Revenue: US$62.4m (up 31% from FY 2022). Net loss: US$79.0m (loss narrowed 9.7% from FY 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 9.9%. Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare Services industry in the US.이익 및 매출 성장 예측NasdaqGS:SOPH - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/2028147-20N/AN/A312/31/2027115-45N/A-26512/31/202693-63N/A-4253/31/202681-81-50-40N/A12/31/202577-79-45-36N/A9/30/202573-75-45-37N/A6/30/202570-73-44-37N/A3/31/202567-66-48-41N/A12/31/202465-62-53-45N/A9/30/202464-71-54-45N/A6/30/202465-67-57-49N/A3/31/202464-73-58-48N/A12/31/202362-79-62-53N/A9/30/202359-69-58-48N/A6/30/202354-78-68-58N/A3/31/202351-82-77-67N/A12/31/202248-87-80-70N/A9/30/202245-95-84-75N/A6/30/202244-93-77-69N/A3/31/202242-86-73-65N/A12/31/202140-74-65-58N/A9/30/202137-63-58-52N/A6/30/202134-52-51-46N/A3/31/202130-41-39-35N/A12/31/202028-39-35-32N/A12/31/201925-34N/A-32N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: SOPH 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 vs 시장: SOPH 향후 3년 동안 수익성이 없을 것으로 예상됩니다.고성장 수익: SOPH 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 대 시장: SOPH 의 수익(연간 21.8%)이 US 시장(연간 12.5%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: SOPH 의 수익(연간 21.8%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: SOPH의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.성장 기업 찾아보기7D1Y7D1Y7D1YHealthcare 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/31 19:30종가2026/07/31 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스SOPHiA GENETICS SA는 7명의 분석가가 다루고 있습니다. 이 중 5명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Mark MassaroBTIGWilliam BonelloCraig-Hallum Capital Group LLCSubhalaxmi NambiGuggenheim Securities, LLC4명의 분석가 더 보기
Price Target Changed • Jul 20Price target increased by 17% to US$9.00Up from US$7.67, the current price target is an average from 4 analysts. New target price is 42% above last closing price of US$6.33. Stock is up 81% over the past year. The company is forecast to post a net loss per share of US$0.84 next year compared to a net loss per share of US$1.17 last year.
공고 • May 06SOPHiA GENETICS SA Reaffirms Earnings Guidance for the Fiscal Year 2026SOPHiA GENETICS SA reaffirmed earnings guidance for the fiscal year 2026. For the year, the company expects revenue to be between $92 million and $94 million, representing approximately 20% to 22% year-over-year growth compared to the fiscal year 2025.
공고 • Mar 03SOPHiA GENETICS SA Reaffirms Earnings Guidance for the Fiscal Year 2026SOPHiA GENETICS SA reaffirmed earnings guidance for the fiscal year 2026. For the year, the company expects revenue to be between $92 million and $94 million, representing approximately 20% to 22% year-over-year growth compared to the fiscal year 2025.
Price Target Changed • Jan 26Price target increased by 9.5% to US$7.67Up from US$7.00, the current price target is an average from 3 analysts. New target price is 44% above last closing price of US$5.32. Stock is up 19% over the past year. The company is forecast to post a net loss per share of US$1.15 next year compared to a net loss per share of US$0.95 last year.
공고 • Nov 05SOPHiA GENETICS SA Revises Earnings Guidance for the Year 2025SOPHiA GENETICS SA revised earnings guidance for the Year 2025. For the period, full year revenue is now expected to be in the range of $75 to $77 million, representing year-over-year growth of 15% to 18%. This compares to the prior range of $72 to $76 million.
Major Estimate Revision • Aug 12Consensus EPS estimates fall by 12%The consensus outlook for fiscal year 2025 has been updated. 2025 expected loss increased from -US$0.96 to -US$1.08 per share. Revenue forecast unchanged at US$74.5m. Healthcare Services industry in the US expected to see average net income growth of 22% next year. Consensus price target down from US$7.25 to US$7.00. Share price fell 8.2% to US$3.14 over the past week.
Recent Insider Transactions Derivative • Jul 21Co-Founder & Executive Chairman notifies of intention to sell stockJurgi Camblong intends to sell 24k shares in the next 90 days after lodging an Intent To Sell Form on the 20th of July. If the sale is conducted around the recent share price of US$5.87, it would amount to US$143k. Jurgi currently holds 3.53m shares (0.042107524875122274 of the company). Company insiders have collectively sold US$175k more than they bought, via options and on-market transactions in the last 12 months.
공고 • Jul 21SOPHiA GENETICS SA to Report Q2, 2026 Results on Aug 04, 2026SOPHiA GENETICS SA announced that they will report Q2, 2026 results on Aug 04, 2026
내러티브 업데이트 • Jul 21SOPH: AI Usage Model And NHS Rollout Will Drive Future UpsideAnalysts have raised their price target on SOPHiA GENETICS stock to $12, citing the company’s AI-driven, usage-based revenue model across clinical and biopharma customers, as well as its exposure to an estimated $40 billion addressable market, as key factors supporting the updated valuation and fair value assumptions. What’s in the News for SOPHiA GENETICS SOPHiA GENETICS completed a follow on equity offering of 10,526,000 common shares at US$4.75 per share, raising approximately US$49.9985 million.
Price Target Changed • Jul 20Price target increased by 17% to US$9.00Up from US$7.67, the current price target is an average from 4 analysts. New target price is 42% above last closing price of US$6.33. Stock is up 81% over the past year. The company is forecast to post a net loss per share of US$0.84 next year compared to a net loss per share of US$1.17 last year.
Recent Insider Transactions Derivative • Jul 01Co-Founder & Executive Chairman notifies of intention to sell stockJurgi Camblong intends to sell 70k shares in the next 90 days after lodging an Intent To Sell Form on the 30th of June. If the sale is conducted around the recent share price of US$5.98, it would amount to US$419k. Jurgi currently holds 3.62m shares (0.04316089777938126 of the company). Company insiders have collectively bought US$10k more than they sold, via options and on-market transactions, in the last 12 months.
공고 • Jun 22SOPHiA GENETICS SA Approves Board ChangesSOPHiA GENETICS SA announced that at the annual general meeting held on June 18, 2026 approved that co-founder Dr. Jurgi Camblong elected as Executive Chairman of the Board, Ross Muken elected as new member of the Board ahead of his appointment as CEO effective July 1, 2026.
New Risk • Jun 21New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 23% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$27m net loss in 3 years). Shareholders have been diluted in the past year (23% increase in shares outstanding).
Seeking Alpha • Jun 18SOPHiA Genetics: Strong Growth Meets A Critical Execution PhaseSummary SOPHiA GENETICS is approaching an inflection point in precision medicine, leveraging AI-driven genomic analysis as sequencing costs decline and data complexity rises. SOPH's platform benefits from a self-reinforcing data flywheel, with 2.5 million genomic profiles and 537 institutions using SOPHiA DDM across 75 countries. Revenue grew 22% year-over-year to $21.7M in 1Q26, with 117% net dollar retention and adjusted gross margin of 75.4%, but profitability remains a key watchpoint. Management targets adjusted EBITDA breakeven by end-2026 and profitability in 2027, supported by cost discipline, new high-value applications, and expanding customer adoption. Read the full article on Seeking Alpha
공고 • Jun 17+ 1 more updateSOPHiA GENETICS SA has completed a Follow-on Equity Offering in the amount of $49.9985 million.SOPHiA GENETICS SA has completed a Follow-on Equity Offering in the amount of $49.9985 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 10,526,000 Price\Range: $4.75
내러티브 업데이트 • Jun 15SOPH: New Partnerships And Ai Collaboration Will Support Future Precision OncologyAnalysts have increased their price target on SOPHiA GENETICS by $1, reflecting updated views on fair value, discount rate, revenue growth, profit margin and future P/E assumptions. What's in the News SOPHiA GENETICS signed a Memorandum of Understanding with Memorial Sloan Kettering Cancer Center to form a joint venture that aims to combine Memorial Sloan Kettering Cancer Center clinical data with the SOPHiA DDM Ai platform for multimodal precision oncology research and deployment.
Recent Insider Transactions • Jun 07Executive VP & CFO recently bought US$99k worth of stockOn the 5th of June, George Cardoza bought around 20k shares on-market at roughly US$4.95 per share. This transaction amounted to 6.9% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was George's only on-market trade for the last 12 months.
내러티브 업데이트 • Jun 01SOPH: NHS Liquid Biopsy Rollout Will Support Future Upside PotentialAnalysts have lifted their price target on SOPHiA GENETICS by $1, citing updated models that reflect a lower discount rate, adjusted revenue growth and profit margin assumptions, and a revised future P/E estimate. What's in the News SOPHiA GENETICS partnered with Synnovis, a leading pathology provider in England, to roll out liquid biopsy testing for lung and breast cancer patients across the U.K. under NHS England's blood test first program, using the MSK-ACCESS® test powered by SOPHiA DDM™.
Recent Insider Transactions Derivative • May 20Executive VP notifies of intention to sell stockPhilippe Menu intends to sell 16k shares in the next 90 days after lodging an Intent To Sell Form on the 19th of May. If the sale is conducted around the recent share price of US$4.69, it would amount to US$73k. Since March 2026, Philippe's direct individual holding has increased from 173.62k shares to 256.39k. Company insiders have collectively sold US$3.4k more than they bought, via options and on-market transactions in the last 12 months.
내러티브 업데이트 • May 15SOPH: New NHS Partnerships Will Support Future Precision Oncology AdoptionAnalysts recently lifted their price target on SOPHiA GENETICS by $1, citing updated assumptions around fair value, discount rate, revenue growth, profit margin and future P/E that together support a slightly higher valuation framework for the stock. Analyst Commentary Recent research has framed the updated price target as a fine tuning of prior assumptions rather than a major shift in conviction.
Reported Earnings • May 06First quarter 2026 earnings: Revenues exceed analysts expectations while EPS lags behindFirst quarter 2026 results: US$0.27 loss per share (further deteriorated from US$0.26 loss in 1Q 2025). Revenue: US$21.7m (up 22% from 1Q 2025). Net loss: US$19.3m (loss widened 11% from 1Q 2025). Revenue exceeded analyst estimates by 6.3%. Earnings per share (EPS) missed analyst estimates by 11%. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Healthcare Services industry in the US. Over the last 3 years on average, earnings per share has increased by 3% per year and the company’s share price has also increased by 3% per year.
공고 • May 06SOPHiA GENETICS SA Reaffirms Earnings Guidance for the Fiscal Year 2026SOPHiA GENETICS SA reaffirmed earnings guidance for the fiscal year 2026. For the year, the company expects revenue to be between $92 million and $94 million, representing approximately 20% to 22% year-over-year growth compared to the fiscal year 2025.
내러티브 업데이트 • Apr 24SOPH: Higher Future P/E Assumptions Will Support Upside PotentialAnalysts lifted their price target on SOPHiA GENETICS by about $0.33 to $8.00, citing updated assumptions around fair value, discount rate, and future P/E that reflect recent research from multiple firms. Analyst Commentary Recent Street research has pointed to updated assumptions around fair value, the discount rate, and forward P/E as the main drivers behind the refreshed $8.00 price target on SOPHiA GENETICS.
공고 • Apr 21SOPHiA GENETICS SA to Report Q1, 2026 Results on May 05, 2026SOPHiA GENETICS SA announced that they will report Q1, 2026 results Pre-Market on May 05, 2026
내러티브 업데이트 • Apr 09SOPH: New U.S. Health System Partnerships Will Drive Future UpsideAnalysts have raised their price target on SOPHiA GENETICS by $1, reflecting updated views on the company’s discount rate, revenue growth outlook, profit margin assumptions, and future P/E as highlighted in recent Street research. Analyst Commentary Recent Street research around SOPHiA GENETICS points to a more cautious tone, even as price targets are adjusted to reflect updated assumptions around discount rates, revenue growth, profit margins, and future P/E multiples.
내러티브 업데이트 • Mar 26SOPH: Higher Future P/E And New U.S. Partnerships Will Support UpsideAnalysts raised their price target on SOPHiA GENETICS by $1, reflecting updated views on factors such as revenue growth expectations, discount rate assumptions, profit margin outlook, and a recalibrated future P/E multiple. Analyst Commentary Bullish Takeaways Bullish analysts see the higher price target as better aligning the stock with updated expectations for revenue growth, which they view as supportive of a richer valuation multiple.
내러티브 업데이트 • Mar 11SOPH: New US Health System Deals Will Support Future UpsideAnalysts lifted their fair value estimate for SOPHiA GENETICS by $1.00 to $7.00, citing updated assumptions for growth, profitability, and future P/E that align with the recent $1 upward move in the Street price target. Analyst Commentary While the latest fair value move to $7.00 lines up with the recent Street price target adjustment, not everyone is leaning positive.
Reported Earnings • Mar 04Full year 2025 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2025 results: US$1.17 loss per share (further deteriorated from US$0.95 loss in FY 2024). Revenue: US$77.3m (up 19% from FY 2024). Net loss: US$79.0m (loss widened 26% from FY 2024). Revenue exceeded analyst estimates by 1.0%. Earnings per share (EPS) missed analyst estimates by 2.0%. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare Services industry in the US. Over the last 3 years on average, earnings per share has increased by 6% per year whereas the company’s share price has increased by 11% per year.
공고 • Mar 03SOPHiA GENETICS SA Reaffirms Earnings Guidance for the Fiscal Year 2026SOPHiA GENETICS SA reaffirmed earnings guidance for the fiscal year 2026. For the year, the company expects revenue to be between $92 million and $94 million, representing approximately 20% to 22% year-over-year growth compared to the fiscal year 2025.
내러티브 업데이트 • Feb 25SOPH: Higher Implied P/E And New Partnerships Will Support Future Platform AdoptionAnalysts have raised their price target on SOPHiA GENETICS by $1, citing updated assumptions on discount rate and long term profitability that result in a slightly higher implied future P/E of 79.26x. Analyst Commentary Analysts raising the price target by $1 are essentially saying that, based on their updated models, the shares now justify a slightly richer valuation, reflected in the implied future P/E of 79.26x.
내러티브 업데이트 • Feb 10SOPH: Oncology Collaboration And New Leadership Will Support Future Platform AdoptionAnalysts have nudged their price target on SOPHiA GENETICS higher by about US$1, reflecting updated views on the company that are consistent with recent Street research commentary. Analyst Commentary Bullish Takeaways Bullish analysts connect the roughly US$1 price target adjustment to refreshed expectations on how SOPHiA GENETICS can execute on its roadmap.
내러티브 업데이트 • Jan 27SOPH: Higher Price Work Will Highlight Expanding Oncology CollaborationsAnalysts have increased their price target on SOPHiA GENETICS by US$1, citing updated assumptions around fair value, discount rates, revenue growth, profit margins, and future P/E expectations. Analyst Commentary Analysts lifting their fair value assumptions by US$1 are essentially fine tuning how they see SOPHiA GENETICS balancing growth potential, execution risk, and valuation multiples such as P/E over time.
Price Target Changed • Jan 26Price target increased by 9.5% to US$7.67Up from US$7.00, the current price target is an average from 3 analysts. New target price is 44% above last closing price of US$5.32. Stock is up 19% over the past year. The company is forecast to post a net loss per share of US$1.15 next year compared to a net loss per share of US$0.95 last year.
공고 • Jan 13+ 2 more updatesSophia Genetics Sa Appoints Kevin Puylaert as Chief Sales Officer, Effective January 2026SOPHiA GENETICS SA announced that Kevin Puylaert, the company's current Managing Director of EMEA, is appointed Chief Sales Officer effective January 2026. Kevin has been with SOPHiA GENETICS for more than 10 years, during which he has held multiple senior leadership roles, and his contributions have been instrumental to the company's growth.
공고 • Jan 12SOPHiA GENETICS SA to Report Q4, 2025 Results on Mar 03, 2026SOPHiA GENETICS SA announced that they will report Q4, 2025 results on Mar 03, 2026
Recent Insider Transactions Derivative • Dec 31Co-Founder notifies of intention to sell stockJurgi Camblong intends to sell 30k shares in the next 90 days after lodging an Intent To Sell Form on the 29th of December. If the sale is conducted around the recent share price of US$4.73, it would amount to US$142k. Since March 2025, Jurgi has owned 2.65m shares directly. There have been no trades via on-market transactions or options from company insiders in the last 12 months.
Recent Insider Transactions Derivative • Nov 12Co-Founder notifies of intention to sell stockJurgi Camblong intends to sell 25k shares in the next 90 days after lodging an Intent To Sell Form on the 10th of November. If the sale is conducted around the recent share price of US$4.37, it would amount to US$108k. Since March 2025, Jurgi has owned 2.65m shares directly. There have been no trades via on-market transactions or options from company insiders in the last 12 months.
공고 • Nov 05SOPHiA GENETICS SA Revises Earnings Guidance for the Year 2025SOPHiA GENETICS SA revised earnings guidance for the Year 2025. For the period, full year revenue is now expected to be in the range of $75 to $77 million, representing year-over-year growth of 15% to 18%. This compares to the prior range of $72 to $76 million.
Reported Earnings • Nov 05Third quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behindThird quarter 2025 results: US$0.30 loss per share (further deteriorated from US$0.28 loss in 3Q 2024). Revenue: US$19.5m (up 23% from 3Q 2024). Net loss: US$20.0m (loss widened 8.6% from 3Q 2024). Revenue exceeded analyst estimates by 7.4%. Earnings per share (EPS) missed analyst estimates by 24%. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare Services industry in the US. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has increased by 37% per year, which means it is tracking significantly ahead of earnings growth.
공고 • Oct 21SOPHiA GENETICS SA to Report Q3, 2025 Results on Nov 04, 2025SOPHiA GENETICS SA announced that they will report Q3, 2025 results Pre-Market on Nov 04, 2025
분석 기사 • Sep 30Market Participants Recognise SOPHiA GENETICS SA's (NASDAQ:SOPH) Revenues Pushing Shares 28% HigherSOPHiA GENETICS SA ( NASDAQ:SOPH ) shares have continued their recent momentum with a 28% gain in the last month alone...
New Risk • Sep 26New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$31m net loss in 3 years). Share price has been volatile over the past 3 months (12% average weekly change).
Recent Insider Transactions Derivative • Sep 24Independent Non-Executive Director notifies of intention to sell stockVincent Ossipow intends to sell 21k shares in the next 90 days after lodging an Intent To Sell Form on the 23rd of September. If the sale is conducted around the recent share price of US$3.93, it would amount to US$83k. Since March 2025, Vincent has owned 443.81k shares directly. There have been no trades via on-market transactions or options from company insiders in the last 12 months.
Recent Insider Transactions Derivative • Aug 20Co-Founder notifies of intention to sell stockJurgi Camblong intends to sell 41k shares in the next 90 days after lodging an Intent To Sell Form on the 19th of August. If the sale is conducted around the recent share price of US$3.49, it would amount to US$142k. Since March 2025, Jurgi has owned 2.65m shares directly. There have been no trades via on-market transactions or options from company insiders in the last 12 months.
Major Estimate Revision • Aug 12Consensus EPS estimates fall by 12%The consensus outlook for fiscal year 2025 has been updated. 2025 expected loss increased from -US$0.96 to -US$1.08 per share. Revenue forecast unchanged at US$74.5m. Healthcare Services industry in the US expected to see average net income growth of 22% next year. Consensus price target down from US$7.25 to US$7.00. Share price fell 8.2% to US$3.14 over the past week.
분석 기사 • Aug 08Analysts Are Updating Their SOPHiA GENETICS SA (NASDAQ:SOPH) Estimates After Its Second-Quarter ResultsNasdaqGS:SOPH 1 Year Share Price vs Fair Value Explore SOPHiA GENETICS's Fair Values from the Community and select...
공고 • Aug 06SOPHiA GENETICS SA has filed a Follow-on Equity Offering in the amount of $50 million.SOPHiA GENETICS SA has filed a Follow-on Equity Offering in the amount of $50 million. Security Name: Ordinary Shares Security Type: Common Stock Transaction Features: At the Market Offering
내러티브 업데이트 • Aug 06Precision Medicine Advances Will Transform Global Healthcare AnalyticsSOPHiA GENETICS' consensus price target has been reduced to $6.75, primarily reflecting lowered revenue growth expectations despite a modest improvement in net profit margin. What's in the News SOPHiA GENETICS reiterated its full-year 2025 revenue guidance of $72 million to $76 million.
Reported Earnings • Aug 05Second quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behindSecond quarter 2025 results: US$0.33 loss per share (further deteriorated from US$0.23 loss in 2Q 2024). Revenue: US$18.3m (up 16% from 2Q 2024). Net loss: US$22.4m (loss widened 48% from 2Q 2024). Revenue exceeded analyst estimates by 4.8%. Earnings per share (EPS) missed analyst estimates by 38%. Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 10.0% growth forecast for the Healthcare Services industry in the US. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.
공고 • Aug 05SOPHiA GENETICS SA Reiterates Earnings Guidance for the Year 2025SOPHiA GENETICS SA reiterated earnings guidance for the year 2025. The company reiterated full-year guidance of revenue between $72 million and $76 million.
공고 • Jul 22SOPHiA GENETICS SA to Report Q2, 2025 Results on Aug 05, 2025SOPHiA GENETICS SA announced that they will report Q2, 2025 results Pre-Market on Aug 05, 2025
분석 기사 • Jul 10Revenues Tell The Story For SOPHiA GENETICS SA (NASDAQ:SOPH) As Its Stock Soars 29%SOPHiA GENETICS SA ( NASDAQ:SOPH ) shareholders have had their patience rewarded with a 29% share price jump in the...
Recent Insider Transactions Derivative • Jun 22Independent Non-Executive Director notifies of intention to sell stockVincent Ossipow intends to sell 18k shares in the next 90 days after lodging an Intent To Sell Form on the 20th of June. If the sale is conducted around the recent share price of US$3.04, it would amount to US$56k. Since March 2025, Vincent has owned 443.81k shares directly. There have been no trades via on-market transactions or options from company insiders in the last 12 months.
Recent Insider Transactions Derivative • May 20Co-Founder notifies of intention to sell stockJurgi Camblong intends to sell 43k shares in the next 90 days after lodging an Intent To Sell Form on the 19th of May. If the sale is conducted around the recent share price of US$2.96, it would amount to US$128k. Since March 2025, Jurgi has owned 2.65m shares directly. There have been no trades via on-market transactions or options from company insiders in the last 12 months.
공고 • May 10SOPHiA GENETICS SA, Annual General Meeting, Jun 18, 2025SOPHiA GENETICS SA, Annual General Meeting, Jun 18, 2025, at 14:00 W. Europe Standard Time. Location: la piece 12, 1180 rolle/vd, Switzerland
Reported Earnings • May 08First quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behindFirst quarter 2025 results: US$0.26 loss per share (further deteriorated from US$0.21 loss in 1Q 2024). Revenue: US$17.8m (up 13% from 1Q 2024). Net loss: US$17.4m (loss widened 27% from 1Q 2024). Revenue exceeded analyst estimates by 6.1%. Earnings per share (EPS) missed analyst estimates by 5.7%. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 10.0% growth forecast for the Healthcare Services industry in the US. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.
공고 • May 06SOPHiA GENETICS SA Provides Reiterates Guidance for the Year 2025SOPHiA GENETICS SA provided reiterated guidance for the year 2025. Full-year revenue between $72 million and $76 million, representing growth of approximately 10% to 17% compared to full year of 2024.
공고 • Apr 22SOPHiA GENETICS SA to Report Q1, 2025 Results on May 06, 2025SOPHiA GENETICS SA announced that they will report Q1, 2025 results Pre-Market on May 06, 2025
새로운 내러티브 • Apr 02Expedited Implementation And New US Signings Will Boost Future Impact Expansion in the U.S. market and major new customer acquisitions like Mount Sinai are poised to significantly boost revenue and market share.
분석 기사 • Mar 20With A 25% Price Drop For SOPHiA GENETICS SA (NASDAQ:SOPH) You'll Still Get What You Pay ForSOPHiA GENETICS SA ( NASDAQ:SOPH ) shareholders won't be pleased to see that the share price has had a very rough...
Reported Earnings • Mar 04Full year 2024 earnings: Revenues and EPS in line with analyst expectationsFull year 2024 results: US$0.95 loss per share (improved from US$1.22 loss in FY 2023). Revenue: US$65.2m (up 4.5% from FY 2023). Net loss: US$62.5m (loss narrowed 21% from FY 2023). Revenue was in line with analyst estimates. Earnings per share (EPS) were also in line with analyst expectations. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 9.7% growth forecast for the Healthcare Services industry in the US. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 34% per year, which means it is significantly lagging earnings.
공고 • Mar 04SOPHiA GENETICS SA Provides Earnings Guidance for the Year 2025SOPHiA GENETICS SA provided earnings guidance for the year 2025. Full-year revenue between $72 million and $76 million, representing growth of approximately 10% to 17% compared to full year of 2024.
Recent Insider Transactions Derivative • Feb 20Co-Founder notifies of intention to sell stockJurgi Camblong intends to sell 90k shares in the next 90 days after lodging an Intent To Sell Form on the 19th of February. If the sale is conducted around the recent share price of US$4.46, it would amount to US$404k. Jurgi currently holds 2.46m shares (0.037027890189429806 of the company). There have been no trades via on-market transactions or options from company insiders in the last 12 months.
공고 • Feb 18SOPHiA GENETICS SA to Report Q4, 2024 Results on Mar 04, 2025SOPHiA GENETICS SA announced that they will report Q4, 2024 results Pre-Market on Mar 04, 2025
공고 • Jan 29SOPHiA GENETICS Launches Comprehensive MRD Tracking CapabilitiesSOPHiA GENETICS has unveiled the OncoPortal™ Mutation Tracker — a longitudinal MRD tracking tool designed for disease monitoring in the context of oncology. This innovation underscores SOPHiA GENETICS' commitment to advancing data-driven approaches for improved oncology insights. Tracking genomic variants across multiple time points in the same patient is becoming increasingly critical in cancer care, particularly for identifying treatment resistance or detecting residual cancer cells, such as in Measurable Residual Disease (MRD) management. The integration of longitudinal tracking capabilities with next-generation sequencing (NGS) allow the parallel detection of cancer-specific genetic mutations at very low frequencies. This combined approach enables early identification of residual disease or emerging variants, providing a more precise assessment of disease burden, better stratification of high-risk patients, and the ability to tailor treatments to the cancer's unique genomic profile. The OncoPortal™ Mutation Tracker augments the SOPHiA DDM™ Platform's core analytical capabilities to allow clinical researchers to longitudinally monitor evolving genomic variants across multiple time points, providing a comprehensive view of disease evolution. The OncoPortal™ Mutation Tracker enhances workflow efficiency for longitudinal variant tracking by offering flexible low frequency variant selection, customizable threshold settings, and reporting features to generate longitudinal graphical representations, simplifying the process of tracking and analyzing genetic changes over time.
Recent Insider Transactions Derivative • Jan 26Co-Founder notifies of intention to sell stockJurgi Camblong intends to sell 19k shares in the next 90 days after lodging an Intent To Sell Form on the 24th of January. If the sale is conducted around the recent share price of US$4.33, it would amount to US$81k. Since March 2024, Jurgi has owned 2.46m shares directly. There have been no trades via on-market transactions or options from company insiders in the last 12 months.
New Risk • Jan 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$43m net loss in 3 years). Share price has been volatile over the past 3 months (11% average weekly change).
분석 기사 • Jan 10Shareholders Should Be Pleased With SOPHiA GENETICS SA's (NASDAQ:SOPH) PriceWhen close to half the companies in the Healthcare Services industry in the United States have price-to-sales ratios...
Recent Insider Transactions Derivative • Dec 27Co-Founder notifies of intention to sell stockJurgi Camblong intends to sell 40k shares in the next 90 days after lodging an Intent To Sell Form on the 24th of December. If the sale is conducted around the recent share price of US$3.31, it would amount to US$134k. Since March 2024, Jurgi has owned 2.46m shares directly. There have been no trades via on-market transactions or options from company insiders in the last 12 months.
New Risk • Nov 11New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.0% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$39m net loss in 3 years). Share price has been volatile over the past 3 months (9.9% average weekly change). Shareholders have been diluted in the past year (2.0% increase in shares outstanding).
공고 • Nov 06SOPHiA GENETICS SA Announces Chief Financial Officer ChangesSOPHiA GENETICS SA announced that Ross Muken, previously Chief Financial Officer ("CFO") and Chief Operating Officer ("COO"), has been promoted to company President, effective November 5, 2024. George Cardoza has been appointed as the company's new CFO. In the newly created role of company President, Ross Muken will oversee SOPHiA GENETICS's global business operations and work even more closely on strategic planning with CEO, Jurgi Camblong. He will continue to lead the company's go-to-market function, including Clinical sales, BioPharma Dx sales, sales support, marketing, customer experience, and operations. Ross joined SOPHiA GENETICS in February 2021 as CFO and was appointed as CFO and COO in March 2023. As CFO, Cardoza will oversee all corporate finance functions, including accounting, financial planning and analysis ("FP&A"), investor relations, internal audit, tax, and treasury. Mr. Cardoza brings more than 30 years of experience in the precision medicine and clinical diagnostics industry, with extensive experience in both financial and operational leadership. Before joining SOPHiA GENETICS, he was the CFO and Head of Service Delivery at Biocartis. Prior, he spent over twelve years with NeoGenomics Laboratories in several executive roles (CFO, President Pharma Services Division, and President and Chief Operating Officer Laboratory Operations), and previously spent more than fourteen years with Quest Diagnostics in various roles including Controller of the Central Region. Throughout his career, Cardoza has shown a strong talent for financial management, strategic planning, and driving businesses towards increasing levels of performance. He has a deep understanding of the industry landscape and a proven track record of success in executing and influencing growth-oriented business strategies. Mr. Cardoza holds a B.S. in Finance and Accounting from Syracuse University and an MBA from Michigan State University.
Reported Earnings • Nov 05Third quarter 2024 earnings: EPS and revenues miss analyst expectationsThird quarter 2024 results: US$0.28 loss per share (further deteriorated from US$0.21 loss in 3Q 2023). Revenue: US$15.9m (down 2.8% from 3Q 2023). Net loss: US$18.4m (loss widened 33% from 3Q 2023). Revenue missed analyst estimates by 1.3%. Earnings per share (EPS) also missed analyst estimates by 19%. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 9.6% growth forecast for the Healthcare Services industry in the US. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 37% per year, which means it is significantly lagging earnings.
공고 • Nov 05SOPHiA GENETICS Re-Affirms Earnings Guidance for the Year 2024SOPHiA GENETICS re-affirmed earnings guidance for the year 2024. For the year, the company expects revenue to be between $65 million and $67 million, representing growth of 4% to 7% compared to Fiscal Year 2023.
공고 • Oct 23SOPHiA GENETICS SA to Report Q3, 2024 Results on Nov 05, 2024SOPHiA GENETICS SA announced that they will report Q3, 2024 results Pre-Market on Nov 05, 2024
Recent Insider Transactions Derivative • Oct 06Co-Founder notifies of intention to sell stockJurgi Camblong intends to sell 21k shares in the next 90 days after lodging an Intent To Sell Form on the 4th of October. If the sale is conducted around the recent share price of US$3.24, it would amount to US$70k. Since March 2024, Jurgi has owned 2.46m shares directly. There have been no trades via on-market transactions or options from company insiders in the last 12 months.
분석 기사 • Oct 03Is SOPHiA GENETICS (NASDAQ:SOPH) A Risky Investment?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
공고 • Sep 16SOPHiA GENETICS Presents Multimodal Research on AI-Driven Patient Stratification at ESMO 2024SOPHiA GENETICS will unveil new research at the European Society for Medical Oncology (ESMO) 2024. The study, conducted in collaboration with AstraZeneca, leverages advanced AI-driven techniques to identify subgroups of stage IV non-small cell lung cancer (NSCLC) patients who could most benefit from the addition of tremelimumab to durvalumab and chemotherapy. The research is a retrospective, multimodal analysis of the POSEIDON Phase 3 clinical trial (NCT03164616). This trial originally demonstrated that the combination of tremelimumab, durvalumab, and chemotherapy significantly increases progression-free survival (PFS) and overall survival (OS) versus chemotherapy in patients with metastatic NSCLC, which lead to approval of this regiment globally in 1L mNSCLC. The SOPHiA GENETICS study used cutting-edge multimodal machine learning models to analyze clinical, biological, genomic, and imaging data, pinpointing patient subgroups who are most likely to benefit from the combination treatment. The research highlighted signatures identifying patients with non-squamous metastatic NSCLC who may derive higher OS benefit from the addition of tremelimumab to durvalumab plus chemotherapy in the first-line treatment setting. In particular, EGFR wild-type, FGFR3 wild-type, CDKN2A wild-type, KRAS mutation, and STK11 mutation comprised elements of a signature was identified as being associated with a higher OS benefit. These findings could have significant implications for the treatment of NSCLC, as it provides an exploration avenue towards a more tailored approach to patient care. The study will be presented as a poster by Ferdinandos Skoulidis, Department of Thoracic Medical Oncology, University of Texas MD Anderson Cancer Center at ESMO 2024 hosted in Barcelona, Spain from September 13-17, 2024. His presentation showcases the operational feasibility and clinical impact of large-scale multimodal analyses in identifying heterogeneous treatment effects in oncology.
Recent Insider Transactions Derivative • Sep 11Independent Non-Executive Director notifies of intention to sell stockKathy Hibbs intends to sell 16k shares in the next 90 days after lodging an Intent To Sell Form on the 9th of September. If the sale is conducted around the recent share price of US$3.75, it would amount to US$60k. Since March 2024, Kathy has owned 37.41k shares directly. There have been no trades via on-market transactions or options from company insiders in the last 12 months.
공고 • Sep 04SOPHiA GENETICS SA Unveils New Generation of the Sophia Ddmtm Platform At Morgan Stanley Healthcare Conference 2024SOPHiA GENETICS launched the new generation of the SOPHiA DDMTM Platform. The new-gen SOPHiA DDMTM Platform offers a new architecture designed to more efficiently compute large amounts of data at-scale, while elevating customer experience with integrated access to multimodal analytics modules. As cancer cases continue to rise across the globe, understanding of the disease becomes more nuanced. Newer, more effective therapies are being developed each day, and data is becoming increasingly critical in diagnosis, therapy selection, and drug development. Since launching the first generation of SOPHiA DDM TM in 2015, the Platform has been at the forefront of these innovations, accelerating the practice of data driven medicine globally as a leading platform in healthcare for using data to improve patient care. Data computed daily by the Platform has surged over the years with over 1.8 million genomic profiles being analyzed on the platform, at a rate of almost 30,000 analyses per month. As the volume and utility of data grows, SOPHiA GENETICS continues to accelerate innovation in the field of data-driven medicine by unveiling best-in-class technology and data science capabilities. The new generation SOPHiA DDM TM Platform offers a new, web-based architecture, which allows the Platform to compute and process data more efficiently by leveraging microservices as well as the newest technologies in cloud computing and GPUs from partners such as NVIDIA and Microsoft. Faster data processing not only optimizes computing, but it also provides answers more rapidly. Customers will experience faster turnaround time from data upload to insights. In addition, more efficient data processing capabilities enable the launch of new capabilities, such as the new whole genome sequencing (WGS) application being released later this year. It also enables new capabilities in multimodal analytics, which require processing of more complex and sizeable data sets across data modalities. Under the new generation of SOPHiA DDMTM, genomic, radiomic, and multimodal analytics capabilities will be offered in a single, integrated workspace. Customers benefit from the three analytics modules by selecting applications that best suit their needs: Genomics: Ingests genomics FASTQ and VCF data to efficiently call, annotate, and pre-classify oncogenic or pathogenic variants. Radiomics: Processes data from various imaging modalities (e.g., CT scans, PET-CT, MRI), segments anatomical areas of interest, and extracts radiomic features for further analysis. Multimodal: Aggregates data from the radiomics and genomics modules, along with processed clinical, biological, and histological data, to train and verify predictive models at the individual patient level.
Major Estimate Revision • Aug 13Consensus revenue estimates decrease by 13%, EPS upgradedThe consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from US$76.0m to US$65.9m. EPS estimate increased from -US$0.995 to -US$0.917 per share. Healthcare Services industry in the US expected to see average net income growth of 26% next year. Consensus price target down from US$8.00 to US$6.00. Share price fell 23% to US$3.19 over the past week.
Recent Insider Transactions Derivative • Aug 11Independent Non-Executive Director notifies of intention to sell stockKathy Hibbs intends to sell 16k shares in the next 90 days after lodging an Intent To Sell Form on the 9th of August. If the sale is conducted around the recent share price of US$3.36, it would amount to US$53k. Since March 2024, Kathy has owned 37.41k shares directly. There have been no trades via on-market transactions or options from company insiders in the last 12 months.
분석 기사 • Aug 09SOPHiA GENETICS SA (NASDAQ:SOPH) Just Reported, And Analysts Assigned A US$6.00 Price TargetShareholders in SOPHiA GENETICS SA ( NASDAQ:SOPH ) had a terrible week, as shares crashed 25% to US$3.36 in the week...
분석 기사 • Aug 08Investors Still Waiting For A Pull Back In SOPHiA GENETICS SA (NASDAQ:SOPH)When you see that almost half of the companies in the Healthcare Services industry in the United States have...
Price Target Changed • Aug 07Price target decreased by 25% to US$6.00Down from US$8.00, the current price target is an average from 4 analysts. New target price is 64% above last closing price of US$3.65. Stock is up 1.1% over the past year. The company is forecast to post a net loss per share of US$0.92 next year compared to a net loss per share of US$1.22 last year.
공고 • Aug 06SOPHiA GENETICS SA Provides Earnings Guidance for the Year 2024SOPHiA GENETICS SA provided earnings guidance for the year 2024. For the period, the company Full-year revenue is now expected to be between $65 million and $67 million, representing growth of 4% to 7% compared to Fiscal Year 2023.
공고 • Jul 23SOPHiA GENETICS SA to Report Q2, 2024 Results on Aug 06, 2024SOPHiA GENETICS SA announced that they will report Q2, 2024 results Pre-Market on Aug 06, 2024
Recent Insider Transactions Derivative • Jul 08Co-Founder notifies of intention to sell stockJurgi Camblong intends to sell 22k shares in the next 90 days after lodging an Intent To Sell Form on the 5th of July. If the sale is conducted around the recent share price of US$4.66, it would amount to US$103k. Since March 2024, Jurgi has owned 2.46m shares directly. There have been no trades via on-market transactions or options from company insiders in the last 12 months.
Board Change • Jul 05Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 2 highly experienced directors. Independent Director Jean-Michel Yves Cossery was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
공고 • Jun 24Sophia Genetics S. A. Launches New Residual Acute Myeloid ApplicationSophia Genetics S.A. announced its new Residual Acute Myeloid (RAM) Application. The new offering expands the company's comprehensive oncology portfolio to support measurable residual disease (MRD) capabilities and will be available to customers worldwide this summer. Acute Myeloid Leukemia (AML) represents about one percent of all cancers worldwide, yet is one of the most common forms of leukemia in adults1. Over 50 percent of AML patients relapse within 3 years after achieving complete remission2, therefore post-treatment monitoring is imperative for AML patients, particularly within the first two years, to help quickly detect any signs of relapse3. MRD solutions can help inform post-remission therapy and identify early relapse, and serve as a primary endpoint in clinical trials, helping researchers detect even the smallest trace of cancer and support better patient outcomes. Next-generation sequencing (NGS)-based MRD testing is among the most advanced in cancer screening and monitoring, and can be found only with highly sensitive methods. The SOPHiA DDM™ RAM Solution provides users with the confidence that MRD will detect even one cancer cell among 10,000 cells. This application will allow users to stay ahead of disease response with the analytical capabilities of the SOPHiA DDM™ Platform, enabling sensitive variant detection down to 0.01% VAF and covering guideline-recommended genes to deliver robust insights for residual acute myeloid. Customers using the SOPHiA DDM™ RAM Solution will have access to longitudinal variant monitoring, allowing them to visualize the mutational landscape for each patient and its evolution over time. The solution also provides users with the most up-to-date databases and customizable reporting features to generate graphical representations and comprehensive MRD reports. Additionally, the SOPHiA DDM™ RAM Solution will continually hone its machine learning algorithms to provide the most accurate MRD results in just four days.
Recent Insider Transactions Derivative • Jun 16Executive VP notifies of intention to sell stockPhilippe Menu intends to sell 33k shares in the next 90 days after lodging an Intent To Sell Form on the 13th of June. If the sale is conducted around the recent share price of US$4.80, it would amount to US$158k. Since March 2024, Philippe has owned 41.75k shares directly. There have been no trades via on-market transactions or options from company insiders in the last 12 months.
Recent Insider Transactions Derivative • May 31Executive VP & Chief Scientific Officer notifies of intention to sell stockZhenyu Xu intends to sell 12k shares in the next 90 days after lodging an Intent To Sell Form on the 29th of May. If the sale is conducted around the recent share price of US$4.92, it would amount to US$59k. Since March 2024, Zhenyu has owned 414.25k shares directly. There have been no trades via on-market transactions or options from company insiders in the last 12 months.
공고 • May 19SOPHiA GENETICS SA, Annual General Meeting, Jun 24, 2024SOPHiA GENETICS SA, Annual General Meeting, Jun 24, 2024, at 14:00 W. Europe Standard Time. Location: offices of sophia genetics sa, la piece 12, 1180 rolle vd, Switzerland
Reported Earnings • May 08First quarter 2024 earnings released: US$0.21 loss per share (vs US$0.31 loss in 1Q 2023)First quarter 2024 results: US$0.21 loss per share (improved from US$0.31 loss in 1Q 2023). Revenue: US$15.8m (up 13% from 1Q 2023). Net loss: US$13.7m (loss narrowed 30% from 1Q 2023). Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare Services industry in the US.
공고 • May 08SOPHiA GENETICS Reiterates Earnings Guidance for the Full Year 2024SOPHiA GENETICS reiterated earnings guidance for the full year 2024. Based on information as of May 7, 2024, SOPHiA GENETICS is reaffirming previously provided guidance of: revenue between $78 million and $81 million, representing growth of 25% to 30% compared to full year 2023 revenue.
공고 • Apr 24SOPHiA GENETICS SA to Report Q1, 2024 Results on May 07, 2024SOPHiA GENETICS SA announced that they will report Q1, 2024 results Pre-Market on May 07, 2024
Major Estimate Revision • Mar 12Consensus EPS estimates fall by 11%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from US$82.1m to US$79.8m. Losses expected to increase from US$0.91 per share to US$1.01. Healthcare Services industry in the US expected to see average net income growth of 32% next year. Consensus price target up from US$8.33 to US$8.67. Share price fell 14% to US$4.85 over the past week.
분석 기사 • Mar 09SOPHiA GENETICS SA (NASDAQ:SOPH) Full-Year Results Just Came Out: Here's What Analysts Are Forecasting For This YearSOPHiA GENETICS SA ( NASDAQ:SOPH ) shareholders are probably feeling a little disappointed, since its shares fell 2.3...
Price Target Changed • Mar 06Price target increased by 8.3% to US$8.67Up from US$8.00, the current price target is an average from 3 analysts. New target price is 73% above last closing price of US$5.01. Stock is up 63% over the past year. The company is forecast to post a net loss per share of US$0.94 next year compared to a net loss per share of US$1.22 last year.
공고 • Mar 06SOPHiA GENETICS SA Provides Earnings Guidance for 2024SOPHiA GENETICS is provided earnings guidance for 2024. For the period, company expects Revenue between $78 million and $81 million, representing growth of 25% to 30% compared to full year 2023.
Reported Earnings • Mar 06Full year 2023 earnings: EPS misses analyst expectationsFull year 2023 results: US$1.22 loss per share (improved from US$1.36 loss in FY 2022). Revenue: US$62.4m (up 31% from FY 2022). Net loss: US$79.0m (loss narrowed 9.7% from FY 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 9.9%. Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare Services industry in the US.
